Both clinical trials evaluated the safety and efficacy of VP-102 compared to placebo. The FDA did not identify any clinical deficiencies. We resubmitted our NDA for VP-102 for the treatment of molluscum in December 2020. In addition, we are also developing VP-102 for the treatment of external genital warts. In July 2020, we received a CRL, from the FDA for our NDA. VP-102 was well-tolerated and no serious adverse events were reported. Safety and efficacy measures were evaluated every three weeks. Sixteen subjects were enrolled in this cohort and 12 completed the trial. In most cases, the submission of an NDA is subject to a substantial application user fee. The FDA may request additional information rather than accept an NDA for filing. The fourth certification described above is known as a paragraph IV certification. The term "remuneration" has been broadly interpreted to include anything of value. There remain judicial and Congressional challenges to certain aspects of the ACA. Other legislative changes have been proposed and adopted since the ACA was enacted. The address of the SEC\'s website is www.sec.gov. We have no products approved for commercialization and have never generated any revenue. We do not have sales or marketing infrastructure. In addition, our collaborators may not comply with these laws. In addition, there is a natural transition period when a new CRO commences work. We rely on our outside counsel to pay these fees. As of December 31, 2020, we had 29 full-time employees. Our stock price may be volatile. As a result, it may be difficult for you to sell shares at an attractive price or at all.